Hank La

2.3k total citations
23 papers, 792 citations indexed

About

Hank La is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Hank La has authored 23 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Oncology and 4 papers in Immunology. Recurrent topics in Hank La's work include Drug Transport and Resistance Mechanisms (5 papers), Cancer therapeutics and mechanisms (4 papers) and Analytical Chemistry and Chromatography (3 papers). Hank La is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Cancer therapeutics and mechanisms (4 papers) and Analytical Chemistry and Chromatography (3 papers). Hank La collaborates with scholars based in United States, France and China. Hank La's co-authors include Harvey Wong, Bruno Alicke, Stephen E. Gould, Xiao Ding, Robert L. Yauch, Yuzhong Deng, Cornelis E. C. A. Hop, Tom Januario, Patrícia Pacheco and Frédéric J. de Sauvage and has published in prestigious journals such as PLoS ONE, Cancer Cell and Clinical Cancer Research.

In The Last Decade

Hank La

23 papers receiving 753 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hank La United States	14	428	221	120	94	91	23	792
Emile G. Plise United States	17	493 1.2×	312 1.4×	77 0.6×	84 0.9×	27 0.3×	39	876
Brinton Seashore‐Ludlow Sweden	20	649 1.5×	186 0.8×	298 2.5×	56 0.6×	64 0.7×	51	1.1k
Joachim Blanz Germany	14	536 1.3×	202 0.9×	183 1.5×	98 1.0×	79 0.9×	31	967
Nerea Gallastegui Germany	13	551 1.3×	238 1.1×	140 1.2×	73 0.8×	31 0.3×	15	745
Mark A. Ashwell United Kingdom	18	556 1.3×	206 0.9×	423 3.5×	144 1.5×	56 0.6×	39	1.2k
F. Anthony Romero United States	14	649 1.5×	108 0.5×	203 1.7×	62 0.7×	71 0.8×	21	1.0k
Krishna G. Vijayendran United States	5	604 1.4×	298 1.3×	195 1.6×	72 0.8×	62 0.7×	5	847
Mark R. Witmer United States	16	378 0.9×	104 0.5×	116 1.0×	26 0.3×	119 1.3×	29	893
Christopher J. Stubbs United Kingdom	15	509 1.2×	158 0.7×	67 0.6×	37 0.4×	27 0.3×	33	785
Ana Negri Spain	18	649 1.5×	119 0.5×	146 1.2×	47 0.5×	49 0.5×	31	1.1k

Countries citing papers authored by Hank La

Since Specialization

Citations

This map shows the geographic impact of Hank La's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hank La with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hank La more than expected).

Fields of papers citing papers by Hank La

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hank La. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hank La. The network helps show where Hank La may publish in the future.

Co-authorship network of co-authors of Hank La

This figure shows the co-authorship network connecting the top 25 collaborators of Hank La. A scholar is included among the top collaborators of Hank La based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hank La. Hank La is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xie, Minli, Harvey Wong, Hank La, et al.. (2019). Cyclodextrin Reduces Intravenous Toxicity of a Model Compound. Journal of Pharmaceutical Sciences. 108(6). 1934–1943. 13 indexed citations

Yen, Ivana, Fergus Shanahan, Mark Merchant, et al.. (2018). Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. Cancer Cell. 34(4). 611–625.e7. 47 indexed citations

Lee, Wendy, James J. Crawford, Ignacio Aliagas, et al.. (2016). Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(15). 3518–3524. 12 indexed citations

René, Olivier, Benjamin P. Fauber, Kerry L. Chapman, et al.. (2016). Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties. Bioorganic & Medicinal Chemistry Letters. 26(18). 4455–4461. 9 indexed citations

Fan, Peter W., Jacob Chen, Hank La, et al.. (2016). Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat. Drug Metabolism Letters. 10(2). 91–100. 5 indexed citations

Hanan, Emily J., Marian C. Bryan, Yuan Chen, et al.. (2015). 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 26(2). 534–539. 39 indexed citations

Fauber, Benjamin P., Alberto Gobbi, Kirk Robarge, et al.. (2015). Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 25(15). 2907–2912. 58 indexed citations

Fauber, Benjamin P., Alberto Gobbi, Pascal Savy, et al.. (2015). Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 25(19). 4109–4113. 10 indexed citations

Fauber, Benjamin P., Olivier René, Yuzhong Deng, et al.. (2015). Discovery of 1-{4-[3-Fluoro-4-((3 S ,6 R )-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C (RORc or RORγ) Inverse Agonist. Journal of Medicinal Chemistry. 58(13). 5308–5322. 46 indexed citations

10.

Crawford, James J., Wendy Lee, Ignacio Aliagas, et al.. (2015). Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors. Journal of Medicinal Chemistry. 58(12). 5121–5136. 29 indexed citations

11.

Fauber, Benjamin P., Olivier René, Gladys de Leon Boenig, et al.. (2014). Reduction in lipophilicity improved the solubility, plasma–protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 24(16). 3891–3897. 39 indexed citations

12.

Hanson, Jesse E., Hank La, Emile G. Plise, et al.. (2013). SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition. PLoS ONE. 8(7). e69964–e69964. 93 indexed citations

13.

Chiang, Po‐Chang, Yong Cui, Yingqing Ran, et al.. (2013). In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound. The AAPS Journal. 15(2). 608–617. 28 indexed citations

14.

Wong, Harvey, Stephen E. Gould, Nageshwar Budha, et al.. (2013). Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist. Drug Metabolism and Disposition. 41(12). 2104–2113. 42 indexed citations

15.

Wong, Harvey, Edna F. Choo, Bruno Alicke, et al.. (2012). Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response. Clinical Cancer Research. 18(14). 3846–3855. 96 indexed citations

16.

Lee, Ho‐June, Gabriele Schaefer, Timothy P. Heffron, et al.. (2012). Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M. Cancer Discovery. 3(2). 168–181. 68 indexed citations

17.

Chiang, Po‐Chang, Yuzhong Deng, Hank La, et al.. (2012). Novel Nanoparticles Formulation for Cassette Dosing via Intravenous Injection in Rats for High Throughput Pharmacokinetic Screening and Potential Applications. Journal of Nanoscience and Nanotechnology. 12(10). 7993–8000. 5 indexed citations

18.

Wong, Harvey, Bruno Alicke, Kristina West, et al.. (2011). Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation. Clinical Cancer Research. 17(14). 4682–4692. 96 indexed citations

19.

Wong, Harvey, Edna F. Choo, Bruno Alicke, et al.. (2011). Abstract A11: Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis.. Molecular Cancer Therapeutics. 10(11_Supplement). A11–A11. 3 indexed citations

20.

Wong, Harvey, Frank‐Peter Theil, Yong Cui, et al.. (2010). Interplay of Dissolution, Solubility, and Nonsink Permeation Determines the Oral Absorption of the Hedgehog Pathway Inhibitor GDC-0449 in Dogs: An Investigation Using Preclinical Studies and Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition. 38(7). 1029–1038. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact